ZYME Zymeworks Inc.
Mergers ·
Zymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative.
Zymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note.
The earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026.
Zymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets.
The warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505.
Zymeworks is a company that uses protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for hard-to-treat diseases. Its structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports an integrated drug development engine. Its pipeline of multifunctional therapeutics is built on multispecific antibody therapeutics (MSATs) and antibody-drug conjugates (ADCs) platforms, aimed at cancer, inflammation and autoimmune disease. Partnerships and collaborations are central to its strategy, as a source of funding for research and development and to share risk, particularly in late-stage development. Through an asset and royalty aggregation strategy, Zymeworks seeks to optimize future cash flows from a growing portfolio of licensed products and product candidates, including Ziihera (zanidatamab-hrii) and pasritamig. As its royalty portfolio matures and generates capital beyond the needs of its operations and strategic investments, the company may allocate capital to stock repurchases.
| Product or program | What it is | Stage |
|---|---|---|
| Ziihera (zanidatamab-hrii) | Licensed product in Zymeworks' royalty portfolio | |
| Pasritamig | Licensed product or candidate in Zymeworks' royalty portfolio |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $106.0 million | $76.3 million |
| Net income (loss) | -$81.1 million | -$122.7 million |
| Cash from operations | -$33.0 million | -$110.1 million |
| Cash and equivalents | $41.2 million | $66.1 million |
Our latest story on this, dated Jun 29, 2026: "Zymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 14, 2026: "Zymeworks authorizes $125.0 million share repurchase program, ends 2025 program". The story links the filing or release it is based on. Read the story.
Zymeworks Inc. trades under the ticker ZYME on NASDAQ.
Zymeworks Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:ZA8.
The SEC Central Index Key (CIK) for Zymeworks Inc. is 1937653. Its filings are on SEC EDGAR.
70,959,241 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Zymeworks Inc. under United States.
Our directory classifies Zymeworks Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Zymeworks Inc. is US98985Y1082.
aibio.space lists Zymeworks Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Zymeworks is a company that uses protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for hard-to-treat diseases. Its structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports an integrated drug development engine.
Ziihera (zanidatamab-hrii): Licensed product in Zymeworks' royalty portfolio
Pasritamig: Licensed product or candidate in Zymeworks' royalty portfolio
$106.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio